儿童肾移植受者免疫抑制治疗的现状与挑战
Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients: Current Status and Challenges
DOI: 10.12677/acm.2025.1541077, PDF,   
作者: 孔繁森*, 杨舒媛, 严早航, 武梅芳:重庆医科大学附属儿童医院泌尿外科,重庆;温 晟, 华 燚#:重庆医科大学附属儿童医院泌尿外科,重庆;国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,结构性出生缺陷与器官修复重建重庆市重点实验室,儿童泌尿生殖发育与组织工程重点实验室,重庆
关键词: 儿童肾移植免疫抑制免疫诱导免疫维持免疫监测个性化用药Pediatric Kidney Transplantation Immunosuppressive Therapy Immune Induction Immune Maintenance Immune Monitoring Personalized Pharmacotherapy
摘要: 相比透析,肾移植是终末期患儿最佳的治疗方式,而免疫抑制治疗则是改善移植受者和移植肾存活率必不可少的手段。但由于儿童在生理、心理、免疫状态、器官功能、原发病等方面与成人存在差异,甚至是不同年龄段的儿童身体状态都存在差异,这就需要在移植术后要有针对性的选择免疫抑制剂及免疫方案。本文从儿童肾移植免疫抑制的现状、当前面临的挑战等方面进行探讨,提高有关个性化用药的思考,以期优化儿童肾移植的免疫抑制管理,以提高儿童移植肾长期存活率、降低慢性排斥反应发生率和避免免疫抑制的并发症。
Abstract: Compared to dialysis, kidney transplantation remains the optimal therapeutic approach for children with end-stage renal disease, while immunosuppressive therapy is indispensable for improving graft and patient survival rates. However, significant differences between children and adults in physiological maturity, psychological development, immune status, organ function, and underlying diseases—as well as distinct physiological characteristics across different pediatric age groups—necessitate personalized selection of immunosuppressive agents and protocols in the post-transplant period. This review examines the current landscape of immunosuppression in pediatric kidney transplantation, highlights persistent challenges in clinical practice, and proposes strategies to refine individualized therapeutic approaches. By optimizing immunosuppressive management, we aim to enhance long-term graft survival, reduce the incidence of chronic rejection, and minimize complications associated with over- or under-immunosuppression in this vulnerable population.
文章引用:孔繁森, 杨舒媛, 严早航, 武梅芳, 温晟, 华燚. 儿童肾移植受者免疫抑制治疗的现状与挑战[J]. 临床医学进展, 2025, 15(4): 1441-1446. https://doi.org/10.12677/acm.2025.1541077

参考文献

[1] 余心逸, 熊华莹, 王墨, 等. 中国儿童慢性肾脏病早期筛查临床实践指南(2021版)计划书[J]. 儿科药学杂志, 2022, 28(1): 1-5.
[2] Verghese, P.S. (2016) Pediatric Kidney Transplantation: A Historical Review. Pediatric Research, 81, 259-264. [Google Scholar] [CrossRef] [PubMed]
[3] 中华医学会器官移植学分会, 中国医疗保健国际交流促进会肾脏移植学分会. 中国肾脏移植受者免疫抑制治疗指南(2023版) [J]. 中华器官移植杂志, 2024, 45(10): 645-663.
[4] Bakr, M.A., Nagib, A.M. and Donia, A.F. (2014) Induction Immunosuppressive Therapy in Kidney Transplantation. Experimental and Clinical Transplantation, 12, 60-69. [Google Scholar] [CrossRef] [PubMed]
[5] 陈刚. 儿童肾移植术后急性排斥反应的特点及思考[J]. 中华器官移植杂志, 2023, 44(2): 65-67.
[6] Dharnidharka, V.R., Fiorina, P. and Harmon, W.E. (2014) Kidney Transplantation in Children. New England Journal of Medicine, 371, 549-558. [Google Scholar] [CrossRef] [PubMed]
[7] Rusai, K. and Szabo, A.J. (2014) Recent Developments in Kidney Transplantation in Children. Current Opinion in Organ Transplantation, 19, 381-386. [Google Scholar] [CrossRef] [PubMed]
[8] 沈黎, 李智平. 儿童他克莫司个体化给药模型的研究进展[J]. 中国药房, 2025, 36(1): 124-128.
[9] Schladt, D.P. and Israni, A.K. (2025) OPTN/SRTR 2023 Annual Data Report: Introduction. American Journal of Transplantation, 25, S11-S21. [Google Scholar] [CrossRef] [PubMed]
[10] Balani, S.S., Jensen, C.J., Kouri, A.M. and Kizilbash, S.J. (2021) Induction and Maintenance Immunosuppression in Pediatric Kidney Transplantation—Advances and Controversies. Pediatric Transplantation, 25, e14077. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, J., Liu, H., Yin, W., Xu, Z., Chen, Z. and Yiu, W. (2022) The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis. Computational Intelligence and Neuroscience, 2022, Article ID: 5717068. [Google Scholar] [CrossRef] [PubMed]
[12] Akiyama, T., Okazaki, H., Takahashi, K., Hasegawa, A., Tanabe, K., Uchida, K., et al. (2004) Mizoribine in Combination Therapy with Tacrolimus for Living Donor Renal Transplantation—Analysis of a Nationwide Study in Japan. Transplantation, 78, 256-257. [Google Scholar] [CrossRef
[13] Krämer, B.K., Klinger, M., Vítko, Š., Glyda, M., Midtvedt, K., Stefoni, S., et al. (2012) Tacrolimus-Based, Steroid-Free Regimens in Renal Transplantation: 3-Year Follow-Up of the ATLAS Trial. Transplantation, 94, 492-498. [Google Scholar] [CrossRef] [PubMed]
[14] Kukla, A., Chen, E., Spong, R., Weber, M., El-Shahawi, Y., Gillingham, K., et al. (2011) Recurrent Glomerulonephritis under Rapid Discontinuation of Steroids. Transplantation, 91, 1386-1391. [Google Scholar] [CrossRef] [PubMed]
[15] Nehus, E., Liu, C., Hooper, D.K., Macaluso, M. and Kim, M. (2015) Clinical Practice of Steroid Avoidance in Pediatric Kidney Transplantation. American Journal of Transplantation, 15, 2203-2210. [Google Scholar] [CrossRef] [PubMed]
[16] Sharma, A., Taverniti, A., Graf, N., Teixeira-Pinto, A., Lewis, J.R., Lim, W.H., et al. (2020) The Association between Human Leukocyte Antigen Eplet Mismatches, De Novo Donor-Specific Antibodies, and the Risk of Acute Rejection in Pediatric Kidney Transplant Recipients. Pediatric Nephrology, 35, 1061-1068. [Google Scholar] [CrossRef] [PubMed]
[17] Ettenger, R., Albrecht, R., Alloway, R., Belen, O., Cavaillé-Coll, M.W., Chisholm-Burns, M.A., et al. (2018) Meeting Report: FDA Public Meeting on Patient-Focused Drug Development and Medication Adherence in Solid Organ Transplant Patients. American Journal of Transplantation, 18, 564-573. [Google Scholar] [CrossRef] [PubMed]
[18] Dobbels, F., Ruppar, T., De Geest, S., Decorte, A., Van Damme-Lombaerts, R. and Fine, R.N. (2009) Adherence to the Immunosuppressive Regimen in Pediatric Kidney Transplant Recipients: A Systematic Review. Pediatric Transplantation, 14, 603-613. [Google Scholar] [CrossRef] [PubMed]
[19] Ettenger, R. and Sarwal, M.M. (2005) Mycophenolate Mofetil in Pediatric Renal Transplantation. Transplantation, 80, S201-S210. [Google Scholar] [CrossRef] [PubMed]
[20] 高悦欣, 郭磊钢, 李琳, 等. 实体器官移植免疫风险评估及监测方法进展[J]. 实用器官移植电子杂志, 2025, 13(1): 60-66.